ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 662

Clinical Significance of Non-Albumin Proteinuria for Severity Assessment of Tubulointerstitial Inflammation in Lupus Nephritis

Oh Chan Kwon1, Seokchan Hong1, Jung Sun Lee2, Byeongzu Ghang1, Doo-Ho Lim3, Wook Jang Seo4, Yong-Gil Kim1, Chang Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 2Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), 4Seoul Veterans Hospital, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: lupus nephritis and proteinuria

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tubulointerstitial inflammation (TI) has been shown to have prognostic significance in renal outcome of lupus nephritis. Considering that the type of protein excreted in urine is different between glomerular disease and tubulointerstitial disease, we aimed to determine whether non-albumin proteinuria is associated with severity of TI in lupus nephritis.

Methods : We included patients with biopsy-confirmed lupus nephritis at a tertiary medical center in Korea from January 2000 to February 2017. Patients were included if their urine protein/creatinine ratio (uPCR) and urine albumin/creatinine ratio (uACR) were simultaneously measured. All included patients met the ACR criteria for classification of systemic lupus erythematosus. Clinical and laboratory variables including C3 and C4 levels as well as anti-double strand DNA (anti-dsDNA) antibody titers were collected. Non-albumin proteinuria was calculated by subtracting uACR from uPCR (uPCR – uACR). Renal pathology including International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification 2003, activity and chronicity indices, and severity of TI was reviewed. Logistic regression analysis was performed to identify the clinical and laboratory parameters associated with TI severity.

Results: Of the total 36 patients, 27 (75%) had no -to -mild TI and 9 (25%) had moderate -to -severe TI. 31 (86.1%) had proliferative type glomerulonephritis (class III ¡¾ V and IV ¡¾ V) and 5 (13.9%) had non-proliferative type glomerulonephritis (class II and V). In logistic regression analysis, the following factors were significantly associated with moderate -to -severe TI: uPCR (odds ratio [OR] 1.599, 95% confidence interval [CI] 1.025-2.494, p = 0.039) and non-albumin proteinuria (uPCR – uACR) (OR 3.558, 95% CI 1.147-11.038, p = 0.028).

Conclusion: In lupus nephritis, non-albumin proteinuria, as assessed by the difference between uPCR and uACR, was associated with severity of TI, to a more relevant degree than uPCR alone. Thus, measuring non-albumin proteinuria can be a valuable non-invasive method for assessing the severity of TI in lupus nephritis.

Table 1. Factors associated with TI severity

 

Odds ratio

95% CI

P value

Age

1.034

0.988-1.082

0.148

Female

4.706

0.511-43.361

0.172

uACR

1.596

0.921-2.764

0.095

uPCR

1.599

1.025-2.494

0.039

uAPR

0.154

0.004-6.650

0.330

uPCR – uACR

3.558

1.147-11.038

0.028

Cr

5.235

0.645-42.506

0.121

C3

1.007

0.964-1.052

0.748

C4

0.942

0.750-1.182

0.604

Anti-dsDNA

0.946

0.850-1.054

0.314

GN activity index

1.086

0.883-1.336

0.435

GN chronicity index

1.000

0.283-3.528

>0.999

ISN/RPS class (proliferative GN)

N/A

N/A

>0.999

 


Disclosure: O. C. Kwon, None; S. Hong, None; J. S. Lee, None; B. Ghang, None; D. H. Lim, None; W. J. Seo, None; Y. G. Kim, None; C. K. Lee, None; B. Yoo, None.

To cite this abstract in AMA style:

Kwon OC, Hong S, Lee JS, Ghang B, Lim DH, Seo WJ, Kim YG, Lee CK, Yoo B. Clinical Significance of Non-Albumin Proteinuria for Severity Assessment of Tubulointerstitial Inflammation in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-significance-of-non-albumin-proteinuria-for-severity-assessment-of-tubulointerstitial-inflammation-in-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-significance-of-non-albumin-proteinuria-for-severity-assessment-of-tubulointerstitial-inflammation-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology